ArticleComputational and structural biotechnology journal2025
Immunolyser 2.0: An advanced computational pipeline for comprehensive analysis of immunopeptidomic data.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phosphorylation of a Tumor-Derived ASXL2 Epitope Remodels the HLA-Bound Peptide Conformational Ensemble and Interaction Network of the Peptide-HLA Complex.Computational and structural biotechnology journal · 2026Article
- STRUMP-I: Structure-Based Machine Learning Approach to pMHC-I Binding Prediction Using Force Field Energy Features.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunopeptidomics interrogates the peptide repertoire presented on the cell surface by major histocompatibility complex (MHC) molecules for T cell immune recognition. Advanced mass-spectrometry-based techniques have enabled rapid accumulation of immunopeptidomic data, posing a significant challenge for automated and efficient analysis of these large-scale datasets. To tackle this challenge, we introduced Immunolyser 1.0, a computational pipeline to streamline key analyses of immunopeptidomic data, including peptide length distribution, motif analysis, peptide clustering, and peptide-MHC binding prediction. Here, we present Immunolyser 2.0 with upgraded functionalities and an improved user interface. Major updates in Immunolyser 2.0 include (i) expanded functionality allowing analysis of murine immunopeptidomic datasets; (ii) a novel algorithm, MHC-TP, to predict the MHC class I haplotype
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.